# US 2023/0057930 A1 · Compositions for alleviating the symptoms of low anterior resection syndrome by topical administration to the neorectum

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2023/0057930 A1
- Document ID: US20230057930A1
- Status: Published application
- Kind: A1
- Application number: 17/758,749
- Filed: 2021-01-14
- Published: 2023-02-23
- Earliest claimed: 2020-01-16
- Assignees: RepoCeuticals A/S
- Applicants: RepoCeuticals A/S
- Inventors: Lars Otto Uttenthal; Lasse Lindblad
- Web page: https://patentgrep.com/patent/US20230057930A1

## CPC

- A61K 31/4045: Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
- A61K 9/0031: {Rectum, anus}
- A61K 9/122: {Foams; Dry foams (edible foams A61K9/0056)}
- A61K 31/10: Sulfides; Sulfoxides; Sulfones
- A61K 47/10: Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
- A61K 47/44: Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin (synthetic glycerides, e.g. medium-chain triglycerides, A61K47/14)
- A61P 1/00: Drugs for disorders of the alimentary tract or the digestive system
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Compositions comprising melatonin and dimethyl sulfoxide are provided for topical administration to the neorectum for use in the alleviation of the symptoms of low anterior resection syndrome.

## Claims

### Claim 1

A method of inhibiting a symptom of low anterior resection syndrome in a patient who has undergone said resection comprising:
topically administering to the mucosa of the neorectum of said patient via the anal canal a composition comprising melatonin and dimethyl sulfoxide (DMSO) formulated in an aqueous solution, as a liquid, gel or foam.

### Claim at position 2

2-6. (canceled)

### Claim 7 (depends on 1)

The method according to claim 1, wherein the total single daily dose of melatonin is dissolved in an aqueous medium containing DMSO 40% (w/w) and glycofurol 20% (w/w).

### Claim 8 (depends on 1)

The method according to claim 1, wherein the administered composition comprises a total single daily dose of 5 mg to 100 mg of melatonin.

### Claim 9 (depends on 1)

The method of claim 1, wherein the administered composition comprises 2.5 mL to 10 mL of liquid or low-viscosity hydrogel.

### Claim 10 (depends on 1)

The method of claim 1, wherein the composition is administered as a volume of 10 mL of foam.

### Claim 11 (depends on 1)

The method of claim 1, wherein a single dose of the composition is administered within one hour before the patient's planned retirement for the night.
